Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.

5.8%; P = 0.90), momelotinib was associated with nominally significant improvements in the rates of total symptom score (TSS) reduction ≥ 50% (26.2% vs. 5.9%; nominal P = 0.0006) and RBC transfusion independence at week 24 (43.3% vs. 21.2%; nominal P = 0.0012) [ 9 ].

also in 7,732 other papers